STAT Plus: Pharmalittle: Trump gives states a tool to lower drug costs, with a catch; ICER updates how it assesses drugs
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to catch up on paperwork, pamper the official mascot, and attend an unusual recital (more on that some other time). And what about you? This may be an opportunity to get organized for tax season, take in a moving picture, or make time for someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon.
The Trump administration unveiled a powerful new tool for states to rein in prescription drug spending, but there’s a catch: States can wield their newfound power only if they accept a cap on the federal funding for their Medicaid program, STAT reports. The tool would effectively help states negotiate lower prices directly with drug makers by denying coverage for certain drugs. Right now, unlike private insurers and some other federal providers, Medicaid programs must cover every drug, which states say hampers their ability to get the best deals.
Continue to STAT Plus to read the full story…
